Editorial: Psychometrics in psychiatry 2022: psychological therapy and psychosomatics DOI Creative Commons
Pasquale Scognamiglio, Phillip J. Tully, Mohsen Khosravi

et al.

Frontiers in Psychiatry, Journal Year: 2023, Volume and Issue: 14

Published: Oct. 18, 2023

EDITORIAL article Front. Psychiatry, 18 October 2023Sec. Psychological Therapy and Psychosomatics Volume 14 - 2023 | https://doi.org/10.3389/fpsyt.2023.1295716

Language: Английский

Evidence for the biopsychosocial model of suicide: a review of whole person modeling studies using machine learning DOI Creative Commons
Earvin S. Tio, Melissa Misztal, Daniel Felsky

et al.

Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 11, 2024

Traditional approaches to modeling suicide-related thoughts and behaviors focus on few data types from often-siloed disciplines. While psychosocial aspects of risk for these phenotypes are frequently studied, there is a lack research assessing their impact in the context biological factors, which important determining an individual's fulsome profile. To directly test this biopsychosocial model suicide identify relative importance predictive measures when considered together, transdisciplinary, multivariate approach needed. Here, we systematically review emerging literature large-scale studies using machine learning integrate psychological, social, factors simultaneously study suicide.

Language: Английский

Citations

5

Neuroimaging and Biosample Collection in the Toronto Adolescent and Youth Cohort Study: Rationale, Methods, and Early Data DOI Creative Commons
Erin W. Dickie, Stephanie H. Ameis, Isabelle Boileau

et al.

Biological Psychiatry Cognitive Neuroscience and Neuroimaging, Journal Year: 2023, Volume and Issue: 9(3), P. 275 - 284

Published: Nov. 17, 2023

The Toronto Adolescent and Youth (TAY) Cohort study will characterize the neurobiological trajectories of psychosis spectrum symptoms (PSS), functioning, suicidality (i.e., suicidal thoughts behaviors) in youth seeking mental health care. Here, we present neuroimaging biosamples component protocol. We also feasibility quality control (QC) metrics for baseline sample collected thus far. includes (aged 11-24 years) referred to child services within a large, tertiary care centre Toronto, Canada, with target recruitment 1500 participants. Participants were offered opportunity provide any or all a: (i) 1-hour MRI scan (EEG if ineligible declined MRI), (ii) blood genomic proteomic data (or saliva collection was not feasible) urine sample, (iii) heart rate recording assess respiratory sinus arrhythmia (RSA) Of first 417 participants consenting participate between May 4, 2021 February 2, 2023, 412 agreed Imaging Biosamples Protocol. these, 334 completed imaging, 341 provided biosample, 338 RSA. 316 three. Following QC, usability high (MRI: T1w 99%, DWI ASL 90%, resting-fMRI 95%, task-fMRI 90%; EEG: 83%; RSA: 99%). consent rates, good completion reported here demonstrate collecting utilising brain imaging large clinical cohort

Language: Английский

Citations

4

Cognitive Dysfunction in the Addictions (CDiA): A Neuron to Neighbourhood Collaborative Research Program on Executive Dysfunction and Functional Outcomes in Outpatients Seeking Treatment for Addiction DOI Creative Commons
Yuliya S. Nikolova, Anthony C. Ruocco, Daniel Felsky

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 31, 2024

Background: Substance use disorders (SUDs) are pressing global public health problems. Executive functions (EFs) prominently featured in mechanistic models of addiction. However, there remain significant gaps our understanding EFs SUDs, including the dimensional relationships to underlying neural circuits, molecular biomarkers, disorder heterogeneity, and functional ability. To improve outcomes for people with interdisciplinary clinical, preclinical services research is needed inform policies interventions aligned biopsychosocial Here, we introduce Cognitive Dysfunction Addictions (CDiA), an integrative team-science translational program, which aims fill these knowledge facilitate discoveries enhance treatments living SUDs. Methods: The CDiA Program comprises seven complementary projects that aim progress EF SUDs investigate new biological treatment approaches. draw on a diverse sample adults aged 18-60 (target N=400) seeking addiction, who followed prospectively over one year identify domains crucial recovery. Projects 1-3 SUD symptoms, brain blood biomarkers their associations both (inhibition, working memory, set-shifting) (disability, quality life). 4 5 evaluate addiction impacts EF: clinical trial repetitive transcranial magnetic stimulation study potential pharmacological rodents. Project 6 links healthcare utilization supplemented qualitative investigation EF-related barriers engagement those substance concerns. 7 uses innovative whole-person modeling integrate multi-modal data generated across projects, applying clustering deep learning methods patient subtypes drive future cross-disciplinary initiatives. Discussion: program has promise bring scientific together uncover ways linked severity These findings, supported by emerging preclinical, service, investigations, will about cognitive dysfunction could care individuals

Language: Английский

Citations

1

Biochemical Signposts: Navigating the Landscape of Early Cancer Diagnosis and Prognostic Insights DOI Open Access

Et al. Khasim Syed

International Journal on Recent and Innovation Trends in Computing and Communication, Journal Year: 2024, Volume and Issue: 11(9), P. 4607 - 4613

Published: Feb. 9, 2024

This exploration investigates the complicated scene of malignant growth from perspective "Biochemical Signs," expecting to upset early analysis and prognostic experiences. Utilizing an exhaustive methodology, biomarkers have distinguished across bosom, lung, prostate tumors, with values going 0.45 3.10. The coordination cutting-edge imaging procedures, including PET X-ray, brought about indicative precision paces 89% 85%, separately. Prognostic investigations divulged biomarkers' shifting effects on understanding endurance, risk proportions 0.70 1.80 p-values featuring factual importance. genomic, proteomic, metabolomic information created all-encompassing sub-atomic profiles, associated unmistakable clinical results. For example, luminal A subtype showed incorporated score 0.85, related a 75% endurance rate. study approves proposed methodology as well lays out its prevalence in exactness, awareness, pertinence when contrasted existing methodologies. blend different types vigor demonstrative devices give establishment groundbreaking headways research customized patient consideration.

Language: Английский

Citations

0

Quality of Life in Mental Disorders DOI
Violeta Enea, Loredana R. Diaconu‐Gherasim

Published: Jan. 1, 2024

Language: Английский

Citations

0

Editorial: Psychometrics in psychiatry 2022: psychological therapy and psychosomatics DOI Creative Commons
Pasquale Scognamiglio, Phillip J. Tully, Mohsen Khosravi

et al.

Frontiers in Psychiatry, Journal Year: 2023, Volume and Issue: 14

Published: Oct. 18, 2023

EDITORIAL article Front. Psychiatry, 18 October 2023Sec. Psychological Therapy and Psychosomatics Volume 14 - 2023 | https://doi.org/10.3389/fpsyt.2023.1295716

Language: Английский

Citations

0